Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 symbols : AGNPF save search
Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study
Published: 2023-08-08 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.089 178.69% 0
|
Health Technology
|
| O: -7.67%
H: 0.0%
C: 0.0%
drug stroke study phase 2
Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
Published: 2023-06-27 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.089 178.69% 0
|
Health Technology
|
| O: 3.1%
H: 0.94%
C: -3.21%
drug group pharmaceuticals program phase 2
Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference
Published: 2023-06-06 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.089 178.69% 0
|
Health Technology
|
| O: 8.43%
H: 2.28%
C: 2.28%
conference pharmaceuticals phase 2
Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study
Published: 2022-10-24 (Crawled : 12:00) - biospace.com/
AGNPF | $0.089 178.69% 0
|
Health Technology
|
| O: 2.87%
H: 0.0%
C: -0.93%
pharmaceuticals trial agreement depression study phase 2
Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference
Published: 2022-08-03 (Crawled : 19:00) - biospace.com/
AGNPF | $0.089 178.69% 0
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -4.93%
conference study phase 2
Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
AGNPF | $0.089 178.69% 0
|
Health Technology
|
| O: 0.12%
H: 1.62%
C: 1.62%
positive study phase 2
Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough
Published: 2022-07-18 (Crawled : 14:00) - biospace.com/
AGNPF | $0.089 178.69% 0
|
Health Technology
|
| O: 1.48%
H: 8.75%
C: 6.25%
fibrosis study phase 2
Algernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended
Published: 2022-06-21 (Crawled : 19:00) - biospace.com/
AGNPF | $0.089 178.69% 0
|
Health Technology
|
| O: 2.48%
H: 0.0%
C: -6.35%
ongoing phase 2
Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough
Published: 2022-06-13 (Crawled : 13:00) - biospace.com/
AGNPF | $0.089 178.69% 0
|
Health Technology
|
| O: 3.66%
H: 0.36%
C: 0.36%
phase 2
Algernon Pharmaceuticals Announces Completion of Enrollment in its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
Published: 2022-02-04 (Crawled : 15:00) - biospace.com/
AGNPF | $0.089 178.69% 0
|
Health Technology
|
| O: -3.69%
H: 1.03%
C: -3.33%
phase 2 als chronic cough enroll
Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study
Published: 2022-01-19 (Crawled : 12:30) - globenewswire.com
AGNPF | $0.089 178.69% 0
|
Health Technology
|
| O: 1.33%
H: 1.73%
C: -14.06%
als trial approval stroke phase 1 phase 2 phase 3
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study
Published: 2022-01-14 (Crawled : 15:00) - biospace.com/
AGNPF | $0.089 178.69% 0
|
Health Technology
|
| O: 9.2%
H: 0.0%
C: -4.78%
fda phase 2 als phase 2b positive chronic cough
Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2
Published: 2021-12-08 (Crawled : 12:30) - globenewswire.com
AGNPF | $0.089 178.69% 0
|
Health Technology
|
| O: 3.62%
H: 10.26%
C: 0.87%
phase 2 drug stroke
Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial
Published: 2021-12-02 (Crawled : 16:00) - biospace.com/
AGNPF | $0.089 178.69% 0
|
Health Technology
|
| O: -0.28%
H: 0.14%
C: -5.57%
phase 2 trial chronic cough enroll
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study
Published: 2021-11-24 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.089 178.69% 0
|
Health Technology
|
| O: 14515.38%
H: 0.0%
C: -1.95%
fda lung cancer phase 1 positive cancer phase 2
Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study
Published: 2021-11-19 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.089 178.69% 0
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -2.5%
stroke phase 1 positive phase 2 phase 3
Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
Published: 2021-10-13 (Crawled : 12:00) - biospace.com/
AGNPF | $0.089 178.69% 0
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: -0.77%
stroke phase 1 phase 2
Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Chronic Cough Phase 2 Study
Published: 2021-10-08 (Crawled : 12:00) - biospace.com/
AGNPF | $0.089 178.69% 0
|
Health Technology
|
| O: -7.45%
H: 16.61%
C: 11.3%
fda phase 2 chronic cough
Algernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil Chronic Cough Study in the U.S.
Published: 2021-09-20 (Crawled : 12:00) - biospace.com/
AGNPF | $0.089 178.69% 0
|
Health Technology
| Email alert
Add to watchlist
phase 2 chronic cough
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
MTH | $154.69 -2.21% 7.56% 64
|
Consumer Durables
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
IHT P | $1.3712 0.82% 6.48% 0
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.